Notably, drug responses to the Erlotinib and Rapamycin showed statistically significant correlations with AML with mutated NPM1 (n = 77, R2 = 0.29, P = 3.7 × 10−7) and inv(3) (n = 6, R2 = 0.91, P = 3.2 × 10−3), respectively. This evidence concerns the gene NPM1 and acute myeloid leukemia.